Pharmacokinetic and pharmacodynamic bioequivalence of biosimilar MYL‐1601D with US and European insulin aspart in healthy volunteers: A randomized, double‐blind, crossover, euglycaemic glucose clamp study
Open Access
- 11 August 2021
- journal article
- research article
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 23 (12) , 2670-2678
Abstract
Aim: To evaluate the pharmacokinetic (PK) and pharmacodynamic (PD) bioequivalence (BE) of MYL‐1601D biosimilar with originator, NovoLog (Ref‐InsAsp‐US), and NovoRapid (Ref‐InsAsp‐EU). Materials and Methods: This was a double‐blind, randomized, crossover study that enrolled 71 healthy subjects to receive a single subcutaneous dose (0.2 U/kg) of each formulation under automated euglycaemic clamp conditions (ClampArt, level 81 mg/dL, duration 12 hours postdose). Primary PK endpoints were area under the plasma insulin aspart concentration‐time curve from 0 to 12 hours (AUC 0‐12h ) and maximum plasma insulin aspart concentration (C max ). Primary PD endpoints were area under the glucose infusion rate (GIR) time curve from 0 to 12 hours (AUC GIR0‐12h ) and maximum GIR (GIR max ). Insulin aspart in plasma was quantified using immunoaffinity purification followed by ultraperformance liquid chromatography and tandem mass spectrometric detection. The pairwise comparisons of geometric least square mean (LS‐mean) ratio for a 90% confidence interval (CI) of primary PK, and 90% CIs (MYL‐1601D vs. Ref‐InsAsp‐US) and 95% CIs (MYL‐1601D vs. Ref‐InsAsp‐EU) of primary PD variables, were to be within 80% to 125% to show BE. Results: MYL‐1601D showed PK BE to both Ref‐InsAsp‐US (AUC 0‐12h geometric LS‐mean ratio 102.17, 90% CI [100.26; 104.11]; C max 106.13 [100.71; 111.85]) and Ref‐InsAsp‐EU (AUC 0‐12h 101.84 [100.04; 103.67]; C max 105.74 [101.09; 110.60]). Likewise, MYL‐1601D showed PD BE to Ref‐InsAsp‐US (AUC GIR_0‐last 99.93; 90% CI [95.74; 104.30]; GIR _max 100.12 [94.46; 106.12]) and Ref‐InsAsp‐EU (AUC GIR_0‐last 96.42; 95% CI [91.17; 101.98]; GIR _max 95.10 [89.37; 101.19]). All three insulin aspart products were well tolerated. Conclusion: MYL‐1601D showed BE to Ref‐InsAsp‐US and Ref‐InsAsp‐EU with a comparable safety profile.Keywords
This publication has 12 references indexed in Scilit:
- Pharmacokinetic and Pharmacodynamic Properties of Faster-Acting Insulin Aspart versus Insulin Aspart Across a Clinically Relevant Dose Range in Subjects with Type 1 Diabetes MellitusClinical Pharmacokinetics, 2016
- How to Assess the Quality of Glucose Clamps? Evaluation of Clamps Performed With ClampArt, a Novel Automated Clamp DeviceJournal of Diabetes Science and Technology, 2015
- Assessment and Reporting of the Clinical Immunogenicity of Therapeutic Proteins and Peptides—Harmonized Terminology and Tactical RecommendationsThe AAPS Journal, 2014
- Insulin aspart improves meal time glycaemic control in patients with Type 2 diabetes: a randomized, stratified, double‐blind and cross‐over trialDiabetic Medicine, 2005
- The effect of improved post-prandial blood glucose control on post-prandial metabolism and markers of vascular risk in people with Type 2 diabetesDiabetes Research and Clinical Practice, 2005
- Measurement of Insulin Absorption and Insulin ActionDiabetes Technology & Therapeutics, 2004
- Insulin aspart vs. human insulin in the management of long‐term blood glucose control in Type 1 diabetes mellitus: a randomized controlled trialDiabetic Medicine, 2000
- Improved postprandial glycemic control with insulin aspart. A randomized double-blind cross-over trial in type 1 diabetes.Diabetes Care, 1999
- Variability of the metabolic effect of soluble insulin and the rapid-acting insulin analog insulin aspart.Diabetes Care, 1998
- Glucose clamp technique: a method for quantifying insulin secretion and resistance.American Journal of Physiology-Endocrinology and Metabolism, 1979